About Bridge Therapeutics
Bridge Therapeutics is a private company based in Birmingham, Alabama. It has reported $2,321,000 raised in two offerings on Form D since February 2018.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 27, 2023 | Dec 18, 2023 | $321,000of $1.5M target | 22 | $14,591 | Debt, Optional conversion into equity at maturityRule 506(c) | Form D ↗ |
| Apr 8, 2019 | Feb 22, 2018amended Apr 24, 2019 | $2,000,000target not set | 11 | $181K | EquityRule 506(c) | Form D/A ↗3 earlier filings |
| Total, two offerings | $2,321,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Bridge Therapeutics's Form D filed Dec 18, 2023.
CP
Christopher Palutis
Director
JM
Joseph Mullin
Director
EK
Elizabeth Kelley
Director
JB
Jason Bailey
Director
TP
Timothy Peara
President
JS
James Sullivan
Executive officer and director
Earlier filings also listed Russell Kelley (promoter, last listed Apr 2019), Kelley Alton (executive officer and director, last listed Apr 2019), Diana Harshbarger (director, last listed Apr 2019) and David Bergstrom (director, last listed Apr 2019).